Inspyr Therapeutics, Inc. Stock Other OTC
Equities
NSPX
US45782A4031
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 241K 331K |
---|---|---|---|---|---|
Net income 2021 | 2M 2.75M | Net income 2022 | -1M -1.37M | EV / Sales 2021 | - |
Net cash position 2021 | 197K 270K | Net Debt 2022 | 305K 419K | EV / Sales 2022 | - |
P/E ratio 2021 |
-0.4
x | P/E ratio 2022 |
-0.23
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 16-10-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Ogilvie
BRD | Director/Board Member | 69 | 08-01-31 |
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Claire Thomas
BRD | Director/Board Member | 68 | 16-10-11 |
1st Jan change | Capi. | |
---|---|---|
+8.38% | 114B | |
+10.13% | 104B | |
-11.69% | 22.5B | |
+2.21% | 22.57B | |
-10.88% | 17.95B | |
-41.90% | 16.48B | |
-16.00% | 15.82B | |
+2.28% | 13.55B | |
+20.54% | 10.99B |